Diabetes Metab J.  2017 Apr;41(2):128-134. 10.4093/dmj.2017.41.2.128.

Lipid Abnormalities in Type 2 Diabetes Mellitus Patients with Overt Nephropathy

• Palazhy S
• Viswanathan V

• KMID: 2376775
• DOI: http://doi.org/10.4093/dmj.2017.41.2.128

Abstract

BACKGROUND
Diabetic nephropathy is a major complication of diabetes and an established risk factor for cardiovascular events. Lipid abnormalities occur in patients with diabetic nephropathy, which further increase their risk for cardiovascular events. We compared the degree of dyslipidemia among type 2 diabetes mellitus (T2DM) subjects with and without nephropathy and analyzed the factors associated with nephropathy among them.
METHODS
In this retrospective study, T2DM patients with overt nephropathy were enrolled in the study group (n=89) and without nephropathy were enrolled in the control group (n=92). Both groups were matched for age and duration of diabetes. Data on total cholesterol (TC), triglycerides (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), urea and creatinine were collected from the case sheets. TG/HDL-C ratio, a surrogate marker for small, dense, LDL particles (sdLDL) and estimated glomerular filtration rate (eGFR) were calculated using equations. Multivariate analysis was done to determine the factors associated with eGFR.
RESULTS
Dyslipidemia was present among 56.52% of control subjects and 75.28% of nephropathy subjects (P=0.012). The percentage of subjects with atherogenic dyslipidemia (high TG+low HDL-C+sdLDL) was 14.13 among controls and 14.61 among nephropathy subjects. Though serum creatinine was not significantly different, mean eGFR value was significantly lower among nephropathy patients (P=0.002). Upon multivariate analysis, it was found that TC (P=0.007) and HDL-C (P=0.06) were associated with eGFR among our study subjects.
CONCLUSION
Our results show that dyslipidemia was highly prevalent among subjects with nephropathy. Regular screening for dyslipidemia may be beneficial in controlling the risk for adverse events among diabetic nephropathy patients.

Keyword

Cardiovascular risk; Diabetic nephropathy; Dyslipidemia; Small, dense low density lipoprotein

MeSH Terms

Biomarkers
Cholesterol
Cholesterol, HDL
Cholesterol, LDL
Creatinine
Diabetes Mellitus, Type 2*
Diabetic Nephropathies
Dyslipidemias
Glomerular Filtration Rate
Humans
Mass Screening
Multivariate Analysis
Retrospective Studies
Risk Factors
Triglycerides
Urea
Biomarkers
Cholesterol
Cholesterol, HDL
Cholesterol, LDL
Creatinine
Triglycerides
Urea

Reference

1. Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans. 2003; 31(Pt 5):1066–1069.

2. Haffner SM. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care. 2003; 26:Suppl 1. S83–S86.

3. Parving HH, Persson F, Rossing P. Microalbuminuria: a parameter that has changed diabetes care. Diabetes Res Clin Pract. 2015; 107:1–8.

4. Samuelsson O, Mulec H, Knight-Gibson C, Attman PO, Kron B, Larsson R, Weiss L, Wedel H, Alaupovic P. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant. 1997; 12:1908–1915.

5. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351:1296–1305.

6. Breyer JA, Bain RP, Evans JK, Nahman NS Jr, Lewis EJ, Cooper M, McGill J, Berl T. Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group. Kidney Int. 1996; 50:1651–1658.

7. Keane WF. The role of lipids in renal disease: future challenges. Kidney Int Suppl. 2000; 75:S27–S31.

8. Trevisan R, Dodesini AR, Lepore G. Lipids and renal disease. J Am Soc Nephrol. 2006; 17(4):Suppl 2. S145–S147.

9. Sharma BK, Jindal SK, Rana DS, Gupta B, Kumar M. Absence of hyperlipidaemia in patients of chronic renal failure in Chandigarh. Indian J Med Res. 1980; 72:461–464.

10. Das BS, Misra SK, Rao DV, Satpathy SR, Bose TK. Serum lipid in chronic renal failure. J Assoc Physicians India. 1984; 32:1019–1021.

11. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl (2011). 2013; 3:259–305.

12. Krolewski AS, Warram JH, Christlieb AR. Hypercholesterolemia: a determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int Suppl. 1994; 45:S125–S131.

13. Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Lackland DT, McGee D, Garvey WT, Klein RL. DCCT/EDIC Research Group. Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. Kidney Int. 2003; 64:817–828.

14. Suchitra MM, Sheshu Kumar M, Bitla AR, Madhusudhana Rao A, Alok S. Atherogenic dyslipidemia in diabetic nephropathy: lipoprotein (a), lipid ratios and atherogenic index. Int J Res Med Sci. 2013; 1:455–459.

15. Jisieike-Onuigbo NN, Unuigbe EI, Kalu OA, Oguejiofor CO, Onuigbo PC. Prevalence of dyslipidemia among adult diabetic patients with overt diabetic nephropathy in Anambra state south-east Nigeria. Niger J Clin Pract. 2011; 14:171–175.

16. Attman PO, Knight-Gibson C, Tavella M, Samuelsson O, Alaupovic P. The compositional abnormalities of lipoproteins in diabetic renal failure. Nephrol Dial Transplant. 1998; 13:2833–2841.

17. Hirano T, Naito H, Kurokawa M, Ebara T, Nagano S, Adachi M, Yoshino G. High prevalence of small LDL particles in non-insulin-dependent diabetic patients with nephropathy. Atherosclerosis. 1996; 123:57–72.

18. Appel GB, Radhakrishnan J, Avram MM, DeFronzo RA, Escobar-Jimenez F, Campos MM, Burgess E, Hille DA, Dickson TZ, Shahinfar S, Brenner BM. RENAAL Study. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care. 2003; 26:1402–1407.

19. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006; 17:2006–2016.

20. Contreras G, Hu B, Astor BC, Greene T, Erlinger T, Kusek JW, Lipkowitz M, Lewis JA, Randall OS, Hebert L, Wright JT Jr, Kendrick CA, Gassman J, Bakris G, Kopple JD, Appel LJ. African-American Study of Kidney Disease, and Hypertension Study Group. Malnutrition-inflammation modifies the relationship of cholesterol with cardiovascular disease. J Am Soc Nephrol. 2010; 21:2131–2142.

21. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA. 2004; 291:451–459.

22. Chen SC, Hung CC, Tsai YC, Huang JC, Kuo MC, Lee JJ, Chiu YW, Chang JM, Hwang SJ, Chen HC. Association of cholesterol levels with mortality and cardiovascular events among patients with CKD and different amounts of proteinuria. Clin J Am Soc Nephrol. 2013; 8:1915–1926.

23. Wang F, Zheng J, Ye P, Luo L, Bai Y, Xu R, Sheng L, Xiao T, Wu H. Association of high-density lipoprotein cholesterol with the estimated glomerular filtration rate in a community-based population. PLoS One. 2013; 8:e79738.

24. Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, Buring JE, Gaziano JM. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003; 14:2084–2091.

25. Chandy A, Pawar B, John M, Isaac R. Association between diabetic nephropathy and other diabetic microvascular and macrovascular complications. Saudi J Kidney Dis Transpl. 2008; 19:924–928.

26. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837–853.

27. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998; 317:713–720.